Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
ASHP.org U.S
Egrifta (2010) is the only GHRH analog with a current indication visceral fat in HIV-associated lipodystrophy supported by Phase 3 RCTs
Most patients begin to notice appetite suppression within the first few weeks of starting treatment, although individual experiences vary
Sublingual is typically appropriate for: Patients with genuine needle aversion who have avoided starting GLP-1 treatment specifically because of the injection requirement
US$ 26.71
US$ 22.42
US$ 22.06
US$ 22.65
US$ 29.06
US$ 20.65
US$ 26.95
US$ 27.76
US$ 28.27
US$ 21.62
US$ 20.78
US$ 27.23
